UG HEALTHCARE CORPORATION LTD (SGX:41A)
UG Healthcare 2HFY20 Preview - Just Getting Started
- We reiterate our positive view on UG Healthcare with the prospect of higher-than-expected ASPs in light of strong glove demand.
- We forecast UG Healthcare to report an 11.9x h-o-h jump in net profit for 2HFY20F, and expect an even better showing in FY21F.
- Despite the recent rally, we believe UG Healthcare’s valuation remains attractive at 12.9x CY21F P/E.
- Reiterate ADD with a higher Target Price of S$3.00.
UG Healthcare's 2HFY20 preview: 11.9x sequential jump in net profit
- UG Healthcare (SGX:41A) is set to release financial results on 11 Aug; we estimate a net profit of S$10.1m for 2HFY20 (Jan 2020 to June 2020), an 11.9x jump on a h-o-h basis. This was likely driven by:
- higher ASPs,
- higher sales volume, and
- cost savings from internal efficiency enhancements and better economies of scale.
- However, we believe that 2HFY20 did not capture the full impact of Covid-19 as glove makers only started to hike ASPs in late-Apr/early-May 20. We believe UG Healthcare can achieve an even better showing in FY21F.
ASPs could increase by more than initially expected
- Our recent channel checks suggest that industry players have hiked their average selling prices at a faster pace in 3QCY20.
- We gather that Top Glove (SGX:BVA)’s ASPs are slated to rise by 25% m-o-m in Aug 20, and it is confident of raising ASPs further by at least 5% m-o-m until end-CY20F. (see also report: Top Glove Corporation - CGS-CIMB Research 2020-07-22: The Show To Go On)
- Kossan also shared that it expects ASPs to rise by 20% in Jul 20 (vs. 2QCY20) and another 20% m-o-m in Aug 20. We believe this reflects the urgent demand for gloves, as daily new cases of Covid-19 worldwide continue to be on an uptrend.
- We conservatively impute +25%/+3% q-o-q ASP growth for UG Healthcare in 1Q/2QFY21F respectively; this raises our FY21-22F EPS by 38.2%-42.8%. Our forecasted EBITDA margins for 2HFY20F/FY21F stand at 19.0%/34.4%, at the lower end of our forecasts for the glove makers under our coverage.
Reiterate ADD, with a higher Target Price of S$3.00
- UG Healthcare remains our preferred pick among the Singapore-listed rubber glove companies, due to its undemanding valuation (c.50% discount to the Malaysia-listed glove sector average CY21F P/E of 26.2x) and OBM business model, which allows it to garner stronger ASP upside potential vs. its peers given the current strong surge in glove demand.
- Our Target Price for UG Healthcare rises to S$3.00, still pegged to 15.0x CY21F P/E (40% discount to peers) to reflect the current favourable operating environment for glove makers.
- See UG Healthcare Share Price; UG Healthcare Target Price; UG Healthcare Analyst Reports; UG Healthcare Dividend History; UG Healthcare Announcements; UG Healthcare Latest News.
- Potential re-rating catalysts include better-than-expected demand for gloves and a higher-than-expected increase in selling prices.
- Downside risks include earlier-than-expected availability of vaccine for Covid-19.
- See also recent reports:
ONG Khang Chuen CFA
CGS-CIMB Research
|
https://www.cgs-cimb.com
2020-07-30
SGX Stock
Analyst Report
3.00
UP
2.100